- Patent Title: Fusion protein containing TGF-β receptor and medicinal uses thereof
-
Application No.: US16610585Application Date: 2018-05-11
-
Publication No.: US11274142B2Publication Date: 2022-03-15
- Inventor: Jinming Gu , Xiao Luo , Weikang Tao
- Applicant: Jiangsu Hengrui Medicine Co., Ltd. , Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicant Address: CN Jiangsu; CN Shanghai
- Assignee: Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee: Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Jiangsu; CN Shanghai
- Agency: Ice Miller LLP
- Priority: CN201710334292.6 20170512
- International Application: PCT/CN2018/086451 WO 20180511
- International Announcement: WO2018/205985 WO 20181115
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K19/00 ; C07K14/71 ; C07K16/32 ; A61P35/00 ; C07K16/28
Abstract:
The present invention provides a fusion protein containing TGF-β receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-βRII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-β receptor, and the use thereof in the preparation of anti-cancer drug.
Public/Granted literature
- US20200157180A1 FUSION PROTEIN CONTAINING TGF-ß RECEPTOR AND MEDICINAL USES THEREOF Public/Granted day:2020-05-21
Information query
